Identification

Name
Dexfenfluramine
Accession Number
DB01191  (APRD00648)
Type
Small Molecule
Groups
Approved, Illicit, Withdrawn
Description

Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.

Structure
Thumb
Synonyms
  • (+)-fenfluramine
  • (S)-fenfluramine
  • (S)-N-Ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
  • D-N-Ethyl-alpha-methyl-m-trifluoromethylphenethylamine
  • Dexfenfluramina
  • Dexfenfluramine
  • Dexfenfluraminum
  • Dextrofenfluramine
External IDs
J13.711A / S 5614
International/Other Brands
Adifax / Redux
Categories
UNII
E35R3G56OV
CAS number
3239-44-9
Weight
Average: 231.2573
Monoisotopic: 231.123484132
Chemical Formula
C12H16F3N
InChI Key
DBGIVFWFUFKIQN-VIFPVBQESA-N
InChI
InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3/t9-/m0/s1
IUPAC Name
ethyl[(2S)-1-[3-(trifluoromethyl)phenyl]propan-2-yl]amine
SMILES
CCN[[email protected]@H](C)CC1=CC=CC(=C1)C(F)(F)F

Pharmacology

Indication

For the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet

Structured Indications
Not Available
Pharmacodynamics

Used to treat diabetes and obesity, Dexfenfluramine decreases caloric intake by increasing serotonin levels in the brain’s synapses. Dexfenfluramine acts as a serotonin reuptake inhibitor. It also causes release of serotonin from the synaptosomes.

Mechanism of action

Dexfenfluramine binds to the serotonin reuptake pump. This causes inhbition of serotonin reuptake. The increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates.

TargetActionsOrganism
ASodium-dependent serotonin transporter
inhibitor
Human
U5-hydroxytryptamine receptor 2C
agonist
Human
Absorption

Well-absorbed from the gastrointestinal tract.

Volume of distribution
Not Available
Protein binding

36%

Metabolism
Not Available
Route of elimination
Not Available
Half life

17-20 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include respiratory failure and cardiac arrest leading to death.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Dexfenfluramine can be increased when it is combined with Abiraterone.Approved
AmiodaroneThe metabolism of Dexfenfluramine can be decreased when combined with Amiodarone.Approved, Investigational
ArtemetherThe metabolism of Dexfenfluramine can be decreased when combined with Artemether.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Dexfenfluramine resulting in a loss in efficacy.Approved
AtomoxetineThe metabolism of Dexfenfluramine can be decreased when combined with Atomoxetine.Approved
AzithromycinThe metabolism of Dexfenfluramine can be decreased when combined with Azithromycin.Approved
BetaxololThe metabolism of Dexfenfluramine can be decreased when combined with Betaxolol.Approved
BortezomibThe metabolism of Dexfenfluramine can be decreased when combined with Bortezomib.Approved, Investigational
BupropionThe metabolism of Dexfenfluramine can be decreased when combined with Bupropion.Approved
CaffeineThe metabolism of Dexfenfluramine can be decreased when combined with Caffeine.Approved
CelecoxibThe metabolism of Dexfenfluramine can be decreased when combined with Celecoxib.Approved, Investigational
ChloroquineThe metabolism of Dexfenfluramine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe metabolism of Dexfenfluramine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
CholecalciferolThe metabolism of Dexfenfluramine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Dexfenfluramine.Approved
CimetidineThe metabolism of Dexfenfluramine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Dexfenfluramine can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Dexfenfluramine can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Dexfenfluramine can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Dexfenfluramine can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Dexfenfluramine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe metabolism of Dexfenfluramine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Dexfenfluramine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Dexfenfluramine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Dexfenfluramine can be decreased when combined with Cocaine.Approved, Illicit
Cyproterone acetateThe serum concentration of Dexfenfluramine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DarifenacinThe metabolism of Dexfenfluramine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Dexfenfluramine can be increased when it is combined with Darunavir.Approved
DeferasiroxThe serum concentration of Dexfenfluramine can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Dexfenfluramine can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Dexfenfluramine can be decreased when combined with Desipramine.Approved
DiphenhydramineThe metabolism of Dexfenfluramine can be decreased when combined with Diphenhydramine.Approved
DosulepinThe metabolism of Dexfenfluramine can be decreased when combined with Dosulepin.Approved
DronedaroneThe metabolism of Dexfenfluramine can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Dexfenfluramine can be decreased when combined with Duloxetine.Approved
EliglustatThe metabolism of Dexfenfluramine can be decreased when combined with Eliglustat.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexfenfluramine.Approved
FluoxetineThe metabolism of Dexfenfluramine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe metabolism of Dexfenfluramine can be decreased when combined with Fluvoxamine.Approved, Investigational
HaloperidolThe metabolism of Dexfenfluramine can be decreased when combined with Haloperidol.Approved
ImipramineThe metabolism of Dexfenfluramine can be decreased when combined with Imipramine.Approved
IndinavirThe metabolism of Dexfenfluramine can be decreased when combined with Indinavir.Approved
IsoniazidThe metabolism of Dexfenfluramine can be decreased when combined with Isoniazid.Approved
KetoconazoleThe metabolism of Dexfenfluramine can be decreased when combined with Ketoconazole.Approved, Investigational
LidocaineThe metabolism of Dexfenfluramine can be decreased when combined with Lidocaine.Approved, Vet Approved
LobeglitazoneThe metabolism of Dexfenfluramine can be decreased when combined with Lobeglitazone.Approved
LopinavirThe metabolism of Dexfenfluramine can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Dexfenfluramine can be decreased when combined with Lorcaserin.Approved
LumefantrineThe metabolism of Dexfenfluramine can be decreased when combined with Lumefantrine.Approved
ManidipineThe metabolism of Dexfenfluramine can be decreased when combined with Manidipine.Approved
MethadoneThe metabolism of Dexfenfluramine can be decreased when combined with Methadone.Approved
MethotrimeprazineThe metabolism of Dexfenfluramine can be decreased when combined with Methotrimeprazine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Dexfenfluramine.Approved, Investigational
MexiletineThe metabolism of Dexfenfluramine can be decreased when combined with Mexiletine.Approved
MidostaurinThe metabolism of Dexfenfluramine can be decreased when combined with Midostaurin.Approved
MirabegronThe metabolism of Dexfenfluramine can be decreased when combined with Mirabegron.Approved
NevirapineThe metabolism of Dexfenfluramine can be decreased when combined with Nevirapine.Approved
NicardipineThe metabolism of Dexfenfluramine can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Dexfenfluramine can be decreased when combined with Nilotinib.Approved, Investigational
OsimertinibThe serum concentration of Dexfenfluramine can be decreased when it is combined with Osimertinib.Approved
PanobinostatThe serum concentration of Dexfenfluramine can be increased when it is combined with Panobinostat.Approved, Investigational
ParoxetineThe metabolism of Dexfenfluramine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Dexfenfluramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PromazineThe metabolism of Dexfenfluramine can be decreased when combined with Promazine.Approved, Vet Approved
QuinidineThe metabolism of Dexfenfluramine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Dexfenfluramine can be decreased when combined with Quinine.Approved
RanolazineThe metabolism of Dexfenfluramine can be decreased when combined with Ranolazine.Approved, Investigational
RitonavirThe metabolism of Dexfenfluramine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Dexfenfluramine can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Dexfenfluramine can be decreased when combined with Ropinirole.Approved, Investigational
SertralineThe metabolism of Dexfenfluramine can be decreased when combined with Sertraline.Approved
SimeprevirThe metabolism of Dexfenfluramine can be decreased when combined with Simeprevir.Approved
StiripentolThe metabolism of Dexfenfluramine can be decreased when combined with Stiripentol.Approved
Tenofovir disoproxilThe metabolism of Dexfenfluramine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Dexfenfluramine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Dexfenfluramine can be decreased when it is combined with Teriflunomide.Approved
TheophyllineThe metabolism of Dexfenfluramine can be decreased when combined with Theophylline.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Dexfenfluramine.Withdrawn
TiclopidineThe metabolism of Dexfenfluramine can be decreased when combined with Ticlopidine.Approved
TipranavirThe metabolism of Dexfenfluramine can be decreased when combined with Tipranavir.Approved, Investigational
TranylcypromineThe metabolism of Dexfenfluramine can be decreased when combined with Tranylcypromine.Approved
VemurafenibThe serum concentration of Dexfenfluramine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Dexfenfluramine can be decreased when combined with Venlafaxine.Approved
ZiprasidoneThe metabolism of Dexfenfluramine can be decreased when combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Dexfenfluramine can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Take with meals.

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15322
KEGG Drug
D07805
PubChem Compound
66265
PubChem Substance
46508388
ChemSpider
59646
BindingDB
85596
ChEBI
439329
ChEMBL
CHEMBL248702
Therapeutic Targets Database
DAP001224
PharmGKB
PA164747936
RxList
RxList Drug Page
Wikipedia
Dexfenfluramine
ATC Codes
A08AA04 — Dexfenfluramine
MSDS
Download (49.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedBasic ScienceAmphetamine Abuse / Amphetamine-Related Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0215 mg/mLALOGPS
logP3.3ALOGPS
logP3.47ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)10.22ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity59.2 m3·mol-1ChemAxon
Polarizability22.69 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9868
Caco-2 permeable+0.7004
P-glycoprotein substrateNon-substrate0.5138
P-glycoprotein inhibitor INon-inhibitor0.5934
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7404
CYP450 2C9 substrateNon-substrate0.8506
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6781
CYP450 1A2 substrateInhibitor0.8859
CYP450 2C9 inhibitorNon-inhibitor0.8616
CYP450 2D6 inhibitorInhibitor0.7253
CYP450 2C19 inhibitorNon-inhibitor0.5205
CYP450 3A4 inhibitorNon-inhibitor0.5219
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6657
Ames testNon AMES toxic0.8808
CarcinogenicityNon-carcinogens0.6397
BiodegradationNot ready biodegradable0.984
Rat acute toxicity3.1255 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9666
hERG inhibition (predictor II)Inhibitor0.7811
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Trifluoromethylbenzenes / Phenylpropanes / Aralkylamines / Dialkylamines / Organopnictogen compounds / Organofluorides / Hydrocarbon derivatives / Alkyl fluorides
Substituents
Amphetamine or derivatives / Trifluoromethylbenzene / Phenylpropane / Aralkylamine / Secondary aliphatic amine / Secondary amine / Alkyl fluoride / Hydrocarbon derivative / Organonitrogen compound / Organofluoride
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
fenfluramine (CHEBI:439329)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Eddahibi S, Adnot S, Frisdal E, Levame M, Hamon M, Raffestin B: Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats. J Pharmacol Exp Ther. 2001 Apr;297(1):148-54. [PubMed:11259539]
  2. Russell BR, Laverty R: The effect of (R)-HA966 or ACEA 1021 on dexfenfluramine or (S)-MDMA-induced changes in temperature, activity, and neurotoxicity. Pharmacol Biochem Behav. 2001 Mar;68(3):565-74. [PubMed:11325413]
  3. Rothman RB, Jayanthi S, Wang X, Dersch CM, Cadet JL, Prisinzano T, Rice KC, Baumann MH: High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. Synapse. 2003 Dec 1;50(3):233-9. [PubMed:14515341]
  4. Johnson GJ, Leis LA, Dunlop PC, Weir EK: The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux. J Thromb Haemost. 2003 Dec;1(12):2663-8. [PubMed:14675103]
  5. Wang X, Baumann MH, Xu H, Rothman RB: 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse. 2004 Sep 15;53(4):240-8. [PubMed:15266556]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Vickers SP, Clifton PG, Dourish CT, Tecott LH: Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. Psychopharmacology (Berl). 1999 Apr;143(3):309-14. [PubMed:10353435]
  2. Wilson AW, Costall B, Neill JC: Manipulation of operant responding for an ethanol-paired conditioned stimulus in the rat by pharmacological alteration of the serotonergic system. J Psychopharmacol. 2000;14(4):340-6. [PubMed:11198050]
  3. Vickers SP, Dourish CT, Kennett GA: Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology. 2001 Aug;41(2):200-9. [PubMed:11489456]
  4. Tomkins DM, Joharchi N, Tampakeras M, Martin JR, Wichmann J, Higgins GA: An investigation of the role of 5-HT(2C) receptors in modifying ethanol self-administration behaviour. Pharmacol Biochem Behav. 2002 Apr;71(4):735-44. [PubMed:11888565]
  5. Bickerdike MJ: 5-HT2C receptor agonists as potential drugs for the treatment of obesity. Curr Top Med Chem. 2003;3(8):885-97. [PubMed:12678838]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:54